Uniqure (NASDAQ:QURE)‘s stock had its “buy” rating reissued by stock analysts at Credit Suisse Group in a research note issued to investors on Friday, AnalystRatings.com reports. They presently have a $76.00 price target on the biotechnology company’s stock. Credit Suisse Group’s price target would indicate a potential upside of 82.12% from the stock’s previous close.
A number of other equities research analysts also recently issued reports on QURE. Wells Fargo & Co downgraded Uniqure from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $90.00 to $56.00 in a research note on Thursday, June 25th. Mizuho restated a “hold” rating and set a $61.00 price target on shares of Uniqure in a research note on Tuesday, July 14th. ValuEngine downgraded Uniqure from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 14th. Chardan Capital cut their price target on Uniqure from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. Finally, BidaskClub downgraded Uniqure from a “sell” rating to a “strong sell” rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $73.92.
Shares of QURE traded up $2.34 during trading hours on Friday, hitting $41.73. The company had a trading volume of 726,949 shares, compared to its average volume of 507,709. The firm has a fifty day moving average price of $49.97 and a 200-day moving average price of $55.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.89 and a current ratio of 12.89. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -13.29 and a beta of 1.24. Uniqure has a 52-week low of $36.20 and a 52-week high of $76.69.
In other Uniqure news, CEO Matthew C. Kapusta sold 5,626 shares of the company’s stock in a transaction on Wednesday, July 22nd. The stock was sold at an average price of $42.31, for a total value of $238,036.06. Following the transaction, the chief executive officer now owns 298,525 shares of the company’s stock, valued at approximately $12,630,592.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert Gut sold 26,875 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $70.00, for a total value of $1,881,250.00. Insiders have sold a total of 40,002 shares of company stock worth $2,614,652 in the last 90 days. 2.66% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. grew its position in shares of Uniqure by 136.4% during the 4th quarter. Victory Capital Management Inc. now owns 6,023 shares of the biotechnology company’s stock worth $432,000 after buying an additional 3,475 shares in the last quarter. Brinker Capital Inc. bought a new position in shares of Uniqure during the 4th quarter worth $206,000. Geode Capital Management LLC grew its position in shares of Uniqure by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 37,487 shares of the biotechnology company’s stock worth $2,686,000 after buying an additional 276 shares in the last quarter. Norges Bank bought a new position in shares of Uniqure during the 4th quarter worth $27,094,000. Finally, Franklin Resources Inc. grew its position in shares of Uniqure by 12.3% during the 4th quarter. Franklin Resources Inc. now owns 610,570 shares of the biotechnology company’s stock worth $43,753,000 after buying an additional 67,020 shares in the last quarter. 79.23% of the stock is currently owned by institutional investors.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Further Reading: Strike Price
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.